Dimerix acquisition of DMX-652 bolsters kidney disease development
Dimerix adds DMX-652, a Phase II-ready AKI asset, strengthening its kidney disease pipeline beyond focal segmental glomerulosclerosis (FSGS).
Read the full article on the original site.
Read Full Article